FAM
CORT icon

Fulcrum Asset Management’s Corcept Therapeutics CORT Stock Holding History

Fulcrum Asset Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.09K Buy
+92
New +$5.55K ﹤0.01% 698

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fulcrum Asset Management's CORT Position: Q2 2026 in Review

Fulcrum Asset Management opened a new position in Corcept Therapeutics (CORT) in Q2 2026: 92 shares worth $8.09K. The stake represents ﹤0.01% of the portfolio and ranks #698 among its holdings.

422 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Fulcrum Asset Management held 92 shares of Corcept Therapeutics worth $8.09K as of Q2 2026.
  • Corcept Therapeutics was a new Fulcrum Asset Management position in Q2 2026.
  • Corcept Therapeutics made up ﹤0.01% of Fulcrum Asset Management's portfolio in Q2 2026, its #698 holding.
  • 422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Fulcrum Asset Management's 13F filing for Q2 2026, filed 18 Aug 2026.